Valiant Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.70 M
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.16 M
- Revenue Growth 21.51%
- Profit Growth -2.24%
- Ebitda 57.17%
- Net Worth 12.60%
- Total Assets 1.03%
About Valiant Life Sciences
Valiant Life Sciences Private Limited (VLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 November 2011 and has a history of 13 years and three months. Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M.
The company currently has active open charges totaling ₹3.16 M.
Ankita Devaliya, Sanjeev Sharma, and Rajesh Sharma serve as directors at the Company.
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24233MP2011PTC027123
- Company No.
027123
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Nov 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Valiant Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Sharma  | Director | 17-Nov-2011 | Current |
| Ankita Devaliya | Director | 17-Nov-2011 | Current |
| Rajesh Sharma | Director | 17-Nov-2011 | Current |
Financial Performance of Valiant Life Sciences.
Valiant Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 21.51% increase. The company also saw a slight decrease in profitability, with a 2.24% decrease in profit. The company's net worth Soared by an impressive increase of 12.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Valiant Life Sciences?
In 2017, Valiant Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.16 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.32 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Mar 2022 | Others | ₹3.16 M | Open |
How Many Employees Work at Valiant Life Sciences?
Unlock and access historical data on people associated with Valiant Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Valiant Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Valiant Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.